Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07624227
PHASE1/PHASE2

The Impact of Cobenfy Maintenance on Cocaine's Effects

Sponsor: Joshua A. Lile, Ph.D.

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine in people with cocaine use disorder. This trial will also provide information about the safety and tolerability of combining Cobenfy and cocaine. Researchers will compare Cobenfy to a placebo (a look-alike substance that contains no drug) to see if Cobenfy is a safe, tolerable and effective at blocking cocaine's effects in participants with cocaine use disorder. Participants will: * Participate in an 11-day inpatient trial * Take Cobenfy or placebo twice per day. * Participate in experimental sessions to test the effects of Cobenfy (or placebo) on the response to cocaine and cocaine self-administration.

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-08-01

Completion Date

2032-06-30

Last Updated

2026-08-18

Healthy Volunteers

No

Interventions

DRUG

Cobenfy

Participants receive Cobenfy maintenance (100 mg xanomeline + 20 mg trospium twice daily) during the inpatient protocol, prior to IV cocaine self-administration.

DRUG

Placebo

Participants receive matching placebo maintenance during the inpatient protocol prior to cocaine self-administration sessions.

Locations (1)

Psychopharmacology of Addiction Laboratory

Lexington, Kentucky, United States